Kremlin plotted to blame unpopular tax rise on west to shield Putin

Russia's stock market closed lower, with the MOEX Russia Index remaining unchanged, indicating a period of stagnation in trading activity. This development reflects ongoing market uncertainties and investor sentiment in the region.

Apple's latest release, the iPhone Air, has experienced disappointing early sales, as consumers appear to prioritize better value and performance over the device's slim design. This trend indicates a potential shift in consumer preferences within the smartphone market.

Bitcoin's recent decline has raised alarms in the cryptocurrency market, indicating potential instability as it falls below $100,000, reversing earlier gains. This downturn has been marked by a series of losses, including a 12-day consecutive drop, reflecting a broader risk-off sentiment among investors.

President Donald Trump's latest diplomatic efforts in Ukraine focus on securing financial agreements as part of his peacemaking initiatives. This approach reflects his ongoing strategy to leverage dealmaking in shaping U.S. foreign policy.

Billionaire hedge fund manager Bill Ackman is reportedly preparing for an initial public offering (IPO) of his firm, Pershing Square Capital Management, anticipated in early 2026, according to the Financial Times. This move has been long awaited in the investment community, signaling a significant transition for Ackman and his hedge fund.

Judge Leonie Brinkema expressed reluctance to mandate a forced sale of Google's advertising business in the ongoing US monopoly case, suggesting that such a dramatic action may not be easily enforceable.

Billionaire investor Bill Ackman is planning to take his hedge fund, Pershing Square, public as early as the first quarter of 2026. This move marks a significant step for Ackman, who has been a prominent figure in the investment community.

Eli Lilly has become the first pharmaceutical company to achieve a market value of $1 trillion, driven by a nearly 40% surge in its shares this year. This growth is largely attributed to the strong demand for its weight-loss and diabetes medications, particularly GLP-1 drugs.